Published in Eur Heart J on February 20, 2009
Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis (2013) 1.02
Impact of body mass index on in-hospital complications in patients undergoing percutaneous coronary intervention in a Japanese real-world multicenter registry. PLoS One (2015) 0.87
Body fat and cardiovascular risk: understanding the obesity paradox. Eur Heart J (2009) 0.84
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet (2005) 13.77
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
Universal definition of myocardial infarction. Circulation (2007) 11.69
Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med (2006) 11.66
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med (2013) 8.76
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28
Circulating microRNAs in patients with coronary artery disease. Circ Res (2010) 6.28
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Should the Babinski sign be part of the routine neurologic examination? Neurology (2005) 5.57
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care (2003) 5.27
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Midlife cardiovascular risk factors and risk of dementia in late life. Neurology (2005) 5.12
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 5.11
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med (2002) 5.10
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 5.08
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90